Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?
Celldex Therapeutics (CLDX) recently experienced an 8.8% stock increase following its inclusion in several Russell growth benchmarks. This inclusion improves visibility and liquidity but doesn't alter the core clinical and execution risks associated with its experimental drug programs. Investors are advised to consider various viewpoints due to the company's current losses and late-stage trial risks.
Price to earnings forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX
This page from TradingView provides financial information for Celldex Therapeutics, Inc. (NASDAQ: CLDX), specifically focusing on its forward Price to Earnings (P/E) ratio. The article indicates that the market is closed and no trades have occurred for CLDX, and lists various data sources and copyright information.
Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus
Celldex Therapeutics (CLDX) has been added to several Russell growth benchmarks,
CLDX SEC Filings - Celldex Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Celldex Therapeutics (CLDX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It details recent filings such as insider stock option grants, beneficial ownership statements, and Q3 2025 financial results showing significant liquidity despite ongoing losses. The reports also highlight R&D spending focused on programs like barzolvolimab, and an insider sale of shares.
Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options
Celldex Therapeutics (NASDAQ: CLDX) granted 93,000 incentive stock options to its SVP & General Counsel, Freddy A. Jimenez, with an exercise price of $34.09 per share. These options, issued under the company's 2021 Omnibus Equity Incentive Plan, will vest 25% on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters, and will expire on June 25, 2036. This grant aligns executive incentives with long-term company performance and continued service.
[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity
Celldex Therapeutics, Inc. (CLDX) reported insider trading activity where director Denice Torres was granted 26,000 non-qualified stock options. These options allow her to buy common stock at an exercise price of $34.09 per share, granted on June 25, 2026, and expiring on June 25, 2036. Following this transaction, Torres directly holds 26,000 derivative securities.
[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity
Celldex Therapeutics director Rita Jain reported the acquisition of 26,000 non-qualified stock options to buy common stock at $34.09 per share. These options were granted under the company’s 2021 Omnibus Equity Incentive Plan at no cost. They become exercisable on June 25, 2027, and will expire on June 25, 2036.
[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity
Celldex Therapeutics director Keith L. Brownlie has received a grant of 26,000 non-qualified stock options as part of his compensation, allowing him to purchase company shares at an exercise price of $34.09 each. These options, granted under the 2021 Omnibus Equity Incentive Plan, become exercisable on June 25, 2027, and expire on June 25, 2036. Following this transaction, Brownlie holds 26,000 derivative securities.
Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant
Celldex Therapeutics' SVP and CFO, Martin Samuel Bates, was granted 93,000 incentive stock options at an exercise price of $34.09 per share under the company's 2021 Omnibus Equity Incentive Plan. The options begin vesting 25% on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters, and expire on June 25, 2036. Following this grant, Bates directly holds 93,000 incentive stock options.
Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant
Celldex Therapeutics, Inc. reported that its SVP and Chief Medical Officer, Diane C. Young, was granted 57,000 Incentive Stock Options. These options, with an exercise price of $34.09 per share, are part of her compensation and will vest over several years, with 25% vesting on June 25, 2027, and the remainder vesting quarterly over the subsequent 12 quarters. The options are set to expire on June 25, 2036.
Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09
Celldex Therapeutics, Inc.'s SVP of Corporate Affairs & Administration, Sarah Cavanaugh, was granted incentive stock options for 95,000 shares at an exercise price of $34.09 per share. The options will vest 25% on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters, and have an expiration date of June 25, 2036. This grant was issued under the company’s 2021 Omnibus Equity Incentive Plan and aims to align employee incentives with stock performance.
Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP
Celldex Therapeutics, Inc. (CLDX) has granted its Senior Vice President and Chief Business Officer, Ronald Pepin, an incentive stock option for 20,000 shares of common stock. The options have an exercise price of $34.09 per share, with 25% vesting on June 25, 2027, and the remainder vesting quarterly over the subsequent 12 quarters. This grant was made under the company’s 2021 Omnibus Equity Incentive Plan and expires on June 25, 2036.
Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan
Celldex Therapeutics, Inc. director Harry Jr Penner was granted 26,000 non-qualified stock options under the company’s 2021 Omnibus Equity Incentive Plan. These options, with an exercise price of $34.09 per share, expire on June 25, 2036, and are compensation-related rather than an open-market transaction. Following this grant, Penner holds 26,000 derivative securities.
Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options
Celldex Therapeutics director Herbert J. Conrad was granted 26,000 non-qualified stock options with an exercise price of $34.09 per share, expiring on June 25, 2036. This grant, under the company's 2021 Omnibus Equity Incentive Plan, increases his total option holdings to 26,000 derivative shares. The Form 4 filing indicates an acquisition by grant, not a stock purchase or sale.
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark
Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 2500 Growth Benchmark, a significant inclusion that indicates its growing presence in the market. The company is a clinical-stage biotechnology firm focused on developing therapeutics for severe inflammatory, allergic, autoimmune, and other diseases by exploring mast cell biology. Its pipeline includes Barzolvolimab (CDX-0159) and CDX-622, both antibody-based therapeutics.
Celldex Therapeutics stock hits 52-week high at 35.8 USD
Celldex Therapeutics (CLDX) stock reached a 52-week high, closing at $35.80 and trading at $35.92, reflecting a 74.25% increase over the past year. This surge is supported by positive clinical trial data for its CDX-622 antibody and barzolvolimab, which has led to maintained or upgraded ratings from UBS, Barclays, and Wells Fargo. Despite its current market performance, InvestingPro analysis indicates that the stock is trading above its Fair Value and is on the "Most Overvalued" list.
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000E Growth Benchmark
Celldex Therapeutics, Inc. (NasdaqCM: CLDX) has been added to the Russell 3000E Growth Benchmark, as announced on June 28, 2026. This news follows several other recent updates for the clinical-stage biotechnology company, including presentations of long-term barzolvolimab results and positive first-in-human results from its Phase 1 study of bispecific CDX-622. Analysts have also adjusted price targets and maintained buy ratings for CLDX shares.
Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX
This article provides an overview of Celldex Therapeutics, Inc. (NASDAQ: CLDX) focusing on its enterprise value to EBIT forward. The content appears to be a financial data page from TradingView, offering financial metrics and other related company information.
Price to earnings forward of Celldex Therapeutics, Inc. – SWB:TCE2
This article displays the "Price to earnings forward" metric for Celldex Therapeutics, Inc. (SWB:TCE2) on the TradingView platform. The page shows that the market is closed, with no trades, and provides navigations related to financial data, news, community, forecasts, and other market analysis tools for the company.
Celldex (CLDX) shareholders back larger equity plan and all directors
Celldex Therapeutics, Inc. shareholders at their 2026 annual meeting approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing shares available for issuance by 3,400,000 to a total of 12,900,000 and clarifying tax withholding terms. All director nominees were elected with significant support, and shareholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. Additionally, a non-binding advisory vote approved the compensation for named executive officers.
Celldex Therapeutics (CLDX) Is Up 5.1% After Barzolvolimab, CDX-622 Mast-Cell Data Update - What's Changed
Celldex Therapeutics saw a 5.1% rise after reporting positive mast-cell data for barzolvolimab and CDX-622. Barzolvolimab demonstrated rapid, durable, and off-treatment improvements in angioedema for chronic spontaneous urticaria patients, while CDX-622 showed dose-dependent mast cell depletion with a favorable safety profile. These results strengthen the scientific case for Celldex's focus on mast cell-driven allergic diseases and its potential to deliver approved products.
Celldex Therapeutics, Inc. Actuals & Estimates (NASDAQ:CLDX)
This article provides an overview of Celldex Therapeutics, Inc. (NASDAQ: CLDX) stock, including its current price, performance, analyst forecasts, historical highs and lows, volatility, market capitalization, and recent financial results. It details the company's earnings, revenue, net income, and employee count, while noting that it does not pay dividends.
CLDX Forecast — Price Target — Prediction for 2027
The article provides a forecast for Celldex Therapeutics, Inc. (CLDX) stock, including analyst price targets, historical performance, and key financial metrics. It highlights that analysts have a max price estimate of $90.00 and a min estimate of $38.00 for CLDX, and the company is expected to release its next earnings report on August 6, 2026. The stock has shown a significant increase over the last year, and its current technical analysis indicates a "strong buy" rating.
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
The Chronic Spontaneous Urticaria (CSU) market is experiencing significant growth, driven by increased disease awareness, improved diagnosis, and a rising number of treatment-refractory patients. Emerging therapies like Barzolvolimab (Celldex Therapeutics), Rilzabrutinib (Sanofi), and Briquilimab (Jasper Therapeutics) are expected to further propel market expansion. The market, which was approximately USD 2 billion in the 7MM in 2025, sees the US as the largest contributor.
Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data
Celldex Therapeutics (CLDX) stock is being re-evaluated after new trial data for its barzolvolimab and CDX-622 programs. While its Price-to-Book ratio of 5.6x suggests it might be overvalued compared to biotech peers (average 2.4x) and the broader industry, a Discounted Cash Flow (DCF) model indicates the stock could be significantly undervalued, with a potential future cash flow value of $82.98 against its current trading price of $32.43. The article highlights mixed signals regarding the company's valuation, despite significant losses, and encourages investors to weigh both perspectives.
Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Celldex Therapeutics Inc (CLDX), noting its current valuation score of 7.85, ranking 191 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -7.60, indicating its position relative to recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Celldex Therapeutics Inc (CLDX) Institutional Confidence
Celldex Therapeutics Inc (CLDX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Despite this high ranking, the institutional shareholding proportion decreased by 26.99% quarter-over-quarter to 96.30%. Bill Nygren | OAKMX is the largest institutional shareholder, holding 4.85% of outstanding shares, though its holdings also decreased by 18.49%.
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Celldex Therapeutics Inc (CLDX) has an earnings forecast score of 8.50, ranking 108th in the Biotechnology & Medical Research industry. Analysts have an average price target of $53.00 for CLDX, with a "Buy" trend based on 16 analyst ratings. The company's expected revenue for the next quarter is 954.44K, and the EPS for the previous quarter was -$1.22, with the next quarter's expected EPS at -$1.07.
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Celldex Therapeutics Inc's (CLDX) financial health, ranking it 157 out of 388 in the Biotechnology & Medical Research industry with a current financial score of 7.06. It notes the company's stable financial status and low operating efficiency. The latest quarterly revenue showed a 97.84% year-over-year decrease to 15.00K, while net profit decreased by 46.27% year-over-year.
Celldex Therapeutics Stock - UBS reiterates Buy after data update
UBS has reiterated its "Buy" rating and $45.00 price target for Celldex Therapeutics stock following an update on clinical trial data. The biotech company is gaining analyst attention for its pipeline strategy, particularly the advancement of barzolvolimab for inflammatory conditions, and completed enrollment in a global late-stage program for the drug. Celldex Therapeutics aims to generate future revenue through out-licensing, partnerships, or direct commercialization of its immunology candidates.
Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential
Celldex Therapeutics (CLDX) saw its stock rise by 12.2% after presenting data for its drugs barzolvolimab and CDX-622. The long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU) suggest potential disease modification, particularly with durable angioedema control. This strengthens Celldex's position in allergy and inflammation, although the company remains unprofitable and faces risks associated with ongoing Phase 3 trials.
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Celldex Therapeutics Inc.'s (CLDX) dividend and stock split history. As of the report, the company has not distributed any dividends over the past five years, nor has it had any recorded stock splits. The current stock price for CLDX is $33.159, with a market capitalization of $2.21 billion.
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Celldex Therapeutics Inc (CLDX) by business segments and region. However, the article explicitly states that relevant data for this breakdown have not been disclosed by the company yet. It primarily displays current stock pricing and general company information, confirming the lack of detailed revenue segmentation.
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX) and MoonLake Immunotherapeutics (MLTX)
LifeSci Capital analysts have issued bullish sentiments for healthcare companies Celldex (CLDX) and MoonLake Immunotherapeutics (MLTX). Sam Slutsky maintained a Buy rating for Celldex with a $67 price target, while Rami Katkhuda maintained a Buy rating for MoonLake Immunotherapeutics with a $33 price target. Both companies received "Strong Buy" or "Moderate Buy" consensus ratings from analysts.
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex Therapeutics announced positive first-in-human results from its Phase 1 study of CDX-622, a novel bispecific antibody, at the European Academy of Allergy and Clinical Immunology Annual Meeting. The data showed that CDX-622 achieved rapid, durable, and dose-dependent reductions in serum tryptase, indicating mast cell depletion, and was well-tolerated. This therapy uniquely targets both soluble stem cell factor (SCF) and TSLP, offering a dual mechanism approach for inflammatory diseases.
Celldex reports positive phase 1 data for CDX-622 antibody
Celldex Therapeutics announced positive Phase 1 data for its bispecific antibody CDX-622, showing it was well-tolerated and reduced serum tryptase, a marker of mast cell activity. The drug targets soluble stem cell factor and thymic stromal lymphopoietin, pathways involved in inflammatory disorders. Analysts have shown optimism, revising earnings estimates upward, and the company plans to initiate further proof-of-concept studies in allergic rhinitis and food allergy.
Barzolvolimab leaves 64% of CSU patients angioedema-free 7 months after dosing
Celldex (NASDAQ: CLDX) reported positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU) patients with angioedema, demonstrating rapid, significant, and durable improvements that persisted seven months after the final dose. Up to 64% of patients with baseline angioedema were angioedema-free at Week 76. These results support the ongoing Phase 3 trials, which have completed enrollment of 1,939 patients, with topline data expected in Q4 2026 and a planned BLA submission in 2027.
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex announced long-term results from its Phase 2 study of barzolvolimab, revealing rapid, significant, and durable improvements in angioedema for patients with chronic spontaneous urticaria (CSU), even seven months post-treatment. These findings, presented at the EAACI Annual Meeting, suggest barzolvolimab could shift CSU treatment from symptom control to disease modification. The positive results support ongoing Phase 3 trials, with topline data expected in Q4 2026.
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex announced long-term results from its Phase 2 study of barzolvolimab for chronic spontaneous urticaria (CSU) at the European Academy of Allergy and Clinical Immunology Annual Meeting. The data showed rapid, significant, and durable improvements in angioedema symptoms, persisting for seven months post-treatment. This supports barzolvolimab's potential for disease modification, with Phase 3 trials concluding enrollment and topline data expected in Q4 2026.
Celldex Presents Positive Phase 1 Results for CDX-622, a Novel Bispecific Antibody for Mast Cell Depletion and TSLP Inhibition at EAACI Annual Meeting
Celldex Therapeutics announced positive Phase 1 clinical trial results for CDX-622, a novel bispecific antibody designed to address inflammatory diseases by targeting soluble stem cell factor (SCF) for mast cell depletion and thymic stromal lymphopoietin (TSLP) inhibition. The study showed that CDX-622 led to rapid, durable, and dose-dependent reductions in serum tryptase, indicating effective mast cell depletion, and was well-tolerated across all dose levels. These promising results support future studies in conditions like allergic rhinitis and food allergies, building on Celldex's leadership in mast cell science.
Celldex reports positive phase 1 data for CDX-622 antibody By Investing.com
Celldex Therapeutics announced positive Phase 1 data for its bispecific antibody CDX-622, which targets soluble stem cell factor and thymic stromal lymphopoietin. The study enrolled 80 healthy participants and indicated that CDX-622 was well-tolerated and showed dose-dependent reductions in a mast cell activity marker. This positive data has led to a significant increase in Celldex's stock over the past week and year, with analysts revising earnings estimates upward and maintaining optimism for the company's clinical pipeline.
New Celldex antibody depletes mast cells in first human test
Celldex (NASDAQ: CLDX) announced positive first-in-human Phase 1 results for its bispecific antibody CDX-622, demonstrating rapid and durable mast cell depletion along with a favorable tolerability profile. This novel antibody targets soluble SCF and TSLP, representing a new approach to treating inflammatory diseases without impacting other KIT-dependent functions. The company plans to advance CDX-622 into further proof-of-concept studies for conditions like asthma, allergic rhinitis, and food allergy, building on its mast cell-focused pipeline alongside barzolvolimab.
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed P/B And DCF Signals
Celldex Therapeutics (CLDX) has seen a recent share price pullback, but its valuation presents mixed signals. The stock trades at a P/B of 4.9x, which is considered overvalued compared to peers, yet a Discounted Cash Flow (DCF) model suggests it's trading at a significant discount to its intrinsic value. Investors are advised to weigh these conflicting signals and consider both risks and rewards.
Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus
Celldex Therapeutics (CLDX) will present new clinical results for barzolvolimab and first-in-human Phase 1 data for CDX-622 at the 2026 European Academy of Allergy and Clinical Immunology Congress. These presentations are crucial for investors to assess Celldex's pipeline progression in mast cell-driven diseases, given the company's current unprofitability and mixed stock performance. The data will help determine the differentiation of its drugs against competitors and clarify its long-term equity story.
Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus
Celldex Therapeutics plans to present new clinical data for barzolvolimab and first-in-human Phase 1 data for CDX-622 at the 2026 European Academy of Allergy and Clinical Immunology Congress. These updates will focus on mast cell-driven diseases and provide important insights into the company's core pipeline, especially given its current unprofitability and reliance on future product development. Investors will be evaluating the efficacy, durability, and safety data for barzolvolimab, and early signals for CDX-622, to assess the company's long-term prospects and compare it against larger competitors.
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex announced upcoming presentations at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, featuring its barzolvolimab and CDX-622 programs. The presentations will include flash talks on barzolvolimab's clinical data in chronic spontaneous urticaria (CSU) and cold urticaria, and a late-breaking poster on the novel bispecific antibody CDX-622's first-in-human results. These presentations highlight Celldex's advancements in targeting mast cells for inflammatory and allergic conditions.
UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating
UBS has increased its price target for Celldex Therapeutics to $45 from $38, while retaining a Buy rating on the stock. This adjustment indicates an updated positive outlook from the firm regarding the company's future performance. Investors and market watchers should note this revised target from UBS.
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex (NASDAQ:CLDX) announced upcoming presentations at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, featuring its barzolvolimab and CDX-622 programs. The presentations will include flash talks on barzolvolimab's clinical program for chronic spontaneous urticaria (CSU) and cold urticaria (ColdU), and a late-breaking poster on the novel bispecific antibody CDX-622. These presentations highlight Celldex's leadership in mast cell targeting therapies and new first-in-human results for CDX-622.
Celldex to present barzolvolimab, CDX-622 data at EAACI congress By Investing.com
Celldex Therapeutics is set to present data from its barzolvolimab and CDX-622 programs at the European Academy of Allergy and Clinical Immunology Annual Congress. The presentations will cover long-term treatment results for barzolvolimab in chronic spontaneous urticaria and cold urticaria, as well as first-in-human results for CDX-622. This follows a successful stock offering and recent analyst upgrades, reflecting growing confidence in the company's pipeline and future prospects.
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex (NASDAQ: CLDX) announced it will present new data from its mast cell-targeting pipeline at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Istanbul. The presentations will cover barzolvolimab for chronic spontaneous and cold urticaria, and first-in-human Phase 1 data for the bispecific antibody CDX-622 in healthy volunteers. These presentations highlight Celldex's leadership in developing treatments for allergic, inflammatory, and autoimmune disorders.
